Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Veronique Sardnal"'
Autor:
Anne Banos, Celia Salanoubat, Odile Beyne-Rauzy, Aline Renneville, Claude Preudhomme, Pascale Cony-Makhoul, Stefan Wickenhauser, Christian Rose, Eric Wattel, Denis Caillot, Julie Lejeune, Francois Dreyfus, François Guilhot, G. Tertian, Agnès Guerci-Bresler, S. Nimuboma, Françoise Isnard, Laurence Sanhes, Kamel Laribi, Stéphane Cheze, Michaela Fontenay, R. Benramdane, B. de Renzis, Dominique Bordessoule, Borhane Slama, Kamal Bouabdallah, Veronique Sardnal, B. Chouffi, Berengere Gruson, Anne-Laure Taksin, Andrea Toma, Sylvie Chevret, Laurence Legros, Karim Maloum, Emmanuel Gyan, R. Petit, C. Gardin, Olivier Kosmider, Carole Soussain, Aspasia Stamatoullas, Jacques Delaunay, Pierre Fenaux
Publikováno v:
Leukemia
Leukemia, 2016, 30 (4), pp.897--905. ⟨10.1038/leu.2015.296⟩
Leukemia, 2016, 30 (4), pp.897--905. 〈10.1038/leu.2015.296〉
Leukemia, 2016, 30 (4), pp.897--905. ⟨10.1038/leu.2015.296⟩
Leukemia, 2016, 30 (4), pp.897--905. 〈10.1038/leu.2015.296〉
International audience; After failure of erythropoiesis-stimulating agents (ESAs), lenalidomide (LEN) yields red blood cell (RBC) transfusion independence (TI) in 20-30% of lower-risk non-del5q myelodysplastic syndrome (MDS). Several observations sug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d4a3e26074be5bccd0fd0cadb50827
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01321412/document
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01321412/document
Autor:
Sophie Kaltenbach, Veronique Sardnal, Francois Dreyfus, Alexandra Rouquette, Olivier Kosmider, Andrea Toma, Pierre Fenaux, Michaela Fontenay
Publikováno v:
Leukemia Research. 37:S83-S84
Autor:
Eric Jourdan, François Dreyfus, Kamel Laribi, Laurence Sanhes, Michaela Fontenay, Veronique Sardnal, Pierre Fenaux, Jacques Delaunay, Olivier Kosmider, Dominique Bordessoule, Andrea Toma, Benoit de Renzis, Borhane Slama, Sylvie Chevret, Anne Banos, Christian Rose, Aspasia Stamatoullas, Denis Caillot, Odile Beyne-Rauzy, Agnes Guercy-Bresler
Publikováno v:
Journal of Clinical Oncology. 31:7002-7002
7002 Background: ESAs, the first line treatments of anemia in non del 5q lower risk MDS, yield only 40-50% responses. LEN gives RBC transfusion independence (TI) in about 25% of ESA resistant (or relapsing) TD lower risk MDS without del 5q (Raza, Blo
Autor:
Jacques Delaunay, Odile Beyne-Rauzy, Marie Passet, Claude Preudhomme, Francois Dreyfus, Andrea Toma, Michaela Fontenay, Veronique Sardnal, Pierre Fenaux, Aline Renneville, Virginie Chesnais, Audrey Gauthier, Olivier Kosmider, Aspasia Stamatoulas
Publikováno v:
ResearcherID
Lenalidomide (Len) is the reference treatment of anemia in patients with del(5q) MDS with half of them being responders. An erythroid response is also achieved in ~25% of non del(5q) low-risk or int-1 MDS patients. The mechanisms of resistance are st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9dfdd6af3d0ef71be4fdedd90b57ddd
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000349242708129&KeyUID=WOS:000349242708129
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000349242708129&KeyUID=WOS:000349242708129